Virax Biolabs Group Ltd. (VRAX)
NASDAQ (CM) NASDAQ (CM) Primary 
Why this biotech stock more than tripled on Thursday
Virax Biolabs (VRAX) shares exploded higher on Thursday morning after management announced a lucrative cross-border commercial breakthrough. In a press release dated July 9th, the company said its UK subsidiary signed an “exclusive” multi-country commercial supply agreement with Fosun Diagnostics, a key division of Shanghai Fosun Pharmaceutical.
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
Virax Biolabs Group Limited (VRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating
H.C. Wainwright initiated coverage on Virax Biolabs Group Limited VRAX, a U.K.-based company focused on detecting immune responses and diagnosing viral diseases.
Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know
Virax Biolabs Group Ltd (NASDAQ: VRAX) saw its shares surge by approximately 45% on Wednesday after announcing a partnership with a leading supplier of Mpox detection kits. The partnership grants Virax the rights to sell RT-PCR tests for Mpox across more than a dozen European countries and several Middle Eastern nations.
Why Is Virax Biolabs (VRAX) Stock Down 15% Today?
Virax Biolabs (NASDAQ: VRAX ) stock is down on Friday after the biotechnology company's shares underwent a massive rally yesterday. That saw shares of VRAX stock close out the prior day of trading up 85.8%.
Why Is Virax Biolabs (VRAX) Stock Up 115% Today?
Virax Biolabs (NASDAQ: VRAX ) stock is rocketing higher on Thursday morning alongside heavy pre-market trading of the biotechnology company's shares. The heavy trading of Virax Biolabs stock has more than 15.2 million shares trading hands as of this writing.
